Skip to main content
SpringerLink
Log in
Book cover

Cytokine Frontiers pp 215–244Cite as

Anti-TNF Therapy: 20 Years from Our First Therapeutic Adventure

  • Chapter
  • First Online:

Abstract

Anti-tumor necrosis factor (TNF) therapy was the first successful anti-cytokine therapy, and its discovery was based on detailed examination of human disease tissue in rheumatoid arthritis and on exploring the dysregulation of cytokine expression within that tissue.

From those first successful clinical trials we conducted in 1992 with infliximab, which were widely publicized more than a year before publication, a competition emerged between a set of companies that had made anti-TNF monoclonals and receptor fusion proteins to treat sepsis to get their products on the market for rheumatoid arthritis (RA). Subsequent clinical trials based on RA success took place in other diseases: Crohn’s disease, ankylosing spondylitis, psoriasis, psoriatic arthritis, and ulcerative colitis. By 1999 etanercept, a tumor necrosis factor-receptor (TNF-R) p75: IgG Fc fusion protein, was approved for RA and infliximab, a chimeric anti-TNF monoclonal antibody, was approved for RA and Crohn’s disease. The foregoing diseases subsequently all became approved indications for anti-TNF therapy that has emerged as the first successful anti-cytokine therapy. By 2013 anti-TNF had become a huge commercial success with global sales of US$27 billion, replacing statins as the most valuable drug class.

But there are many challenges remaining. There are many other diseases that could benefit from anti-TNF therapy, and we discuss many but not all of them in this review. And then, it is clear that anti-TNF therapy is not a cure. We need to get closer to a cure and find complementary therapeutics that when added to anti-TNF would take us closer to a cure. Doing so safely and reproducibly is a challenge, but great understanding of the pathogenesis of RA and how anti-TNF works will be helpful.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  • The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group (1999) TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 53:457–465

    Google Scholar 

  • Aerts NE, De Knop KJ, Leysen J, Ebo DG, Bridts CH, Weyler JJ, Stevens WJ, De Clerck LS (2010) Increased IL-17 production by peripheral T helper cells after tumour necrosis factor blockade in rheumatoid arthritis is accompanied by inhibition of migration-associated chemokine receptor expression. Rheumatology 49:2264–2272

    CAS  PubMed  Google Scholar 

  • Alexopoulou L, Kranidioti K, Xanthoulea S, Denis M, Kotanidou A, Douni E, Blackshear PJ, Kontoyiannis DL, Kollias G (2006) Transmembrane TNF protects mutant mice against intracellular bacterial infections, chronic inflammation and autoimmunity. Eur J Immunol 36:2768–2780

    CAS  PubMed  Google Scholar 

  • Altintas MM, Azad A, Nayer B, Contreras G, Zaias J, Faul C, Reiser J, Nayer A (2011) Mast cells, macrophages, and crown-like structures distinguish subcutaneous from visceral fat in mice. J Lipid Res 52:480–488

    CAS  PubMed  Google Scholar 

  • Alzabin S, Abraham SM, Taher TE, Palfreeman A, Hull D, McNamee KE, Jawad A, Pathan E, Kinderlerer A, Taylor PC, Williams RO, Mageed R (2012) Incomplete response of inflammatory arthritis to TNFα blockade is associated with the Th17 pathway. Ann Rheum Dis 71:1471–1478

    Google Scholar 

  • Arnett HA, Mason J, Marino M, Suzuki K, Matsushima GK, Ting JP (2001) TNF alpha promotes proliferation of oligodendrocyte progenitors and remyelination. Nat Neurosci 4:1116–1122

    CAS  PubMed  Google Scholar 

  • Avina-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D (2008) Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 59:1690–1697

    PubMed  Google Scholar 

  • Baker D, Butler D, Scallon BJ, O’Neill JK, Turk JL, Feldmann M (1994) Control of established experimental allergic encephalomyelitis by inhibitionof tumor necrosis factor activity within the central nervous system using monoclonal antibodies and TNF receptor–immunoglobulin fusion proteins. Eur J Immunol 24:2040–2048

    CAS  PubMed  Google Scholar 

  • Balosso S, Ravizza T, Perego C, Peschon J, Campbell IL, De Simoni MG, Vezzani A (2005) Tumor necrosis factor-alpha inhibits seizures in mice via p75 receptors. Ann Neurol 57:804–812

    CAS  PubMed  Google Scholar 

  • Barbara JA, Smith WB, Gamble JR, Van Ostade X, Vandenabeele P, Tavernier J, Fiers W, Vadas MA, Lopez AF (1994) Dissociation of TNF-alpha cytotoxic and proinflammatory activities by p55 receptor- and p75 receptor-selective TNF-alpha mutants. EMBO J 13:843–850

    CAS  PubMed  Google Scholar 

  • Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, Castner BJ, Stocking KL, Reddy P, Srinivasan S, Nelson N, Boiani N, Schooley KA, Gerhart M, Davis R, Fitzner JN, Johnson RS, Paxton RJ, March CJ, Cerretti DP (1997) A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature (Lond) 385:729–733

    CAS  Google Scholar 

  • Bluml S, Scheinecker C, Smolen JS, Redlich K (2012) Targeting TNF receptors in rheumatoid arthritis. Int Immunol 24:275–281

    PubMed  Google Scholar 

  • Bosello S, De Santis M, Tolusso B, Zoli A, Ferraccioli G (2005) Tumor necrosis factor-alpha inhibitor therapy in erosive polyarthritis secondary to systemic sclerosis. Ann Intern Med 143:918–920

    PubMed  Google Scholar 

  • Bozkurt B, Kribbs SB, Clubb FJ Jr, Michael LH, Didenko VV, Hornsby PJ, Seta Y, Oral H, Spinale FG, Mann DL (1998) Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. Circulation 97:1382–1391

    CAS  PubMed  Google Scholar 

  • Brennan FM, Chantry D, Jackson A, Maini R, Feldmann M (1989) Inhibitory effect of TNFα antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 2:244–247

    CAS  PubMed  Google Scholar 

  • Brennan FM, Browne KA, Green PA, Jaspar JM, Maini RN, Feldmann M (1997) Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumour necrosis factor-alpha (cA2) therapy. Br J Rheumatol 36:643–650

    CAS  PubMed  Google Scholar 

  • Bruce AJ, Boling W, Kindy MS, Peschon J, Kraemer PJ, Carpenter MK, Holtsberg FW, Mattson MP (1996) Altered neuronal and microglial responses to excitotoxic and ischemic brain injury in mice lacking TNF receptors. Nat Med 2:788–794

    CAS  PubMed  Google Scholar 

  • Carmona L, Descalzo MA, Perez-Pampin E, Ruiz-Montesinos D, Erra A, Cobo T, Gomez-Reino JJ (2007) All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists. Ann Rheum Dis 66:880–885

    CAS  PubMed  Google Scholar 

  • Carson MJ, Bilousova TV, Puntambekar SS, Melchior B, Doose JM, Ethell IM (2007) A rose by any other name? The potential consequences of microglial heterogeneity during CNS health and disease. Neurotherapeutics 4:571–579

    CAS  PubMed  Google Scholar 

  • Castillo J, Moro MA, Blanco M, Leira R, Serena J, Lizasoain I, Davalos A (2003) The release of tumor necrosis factor-alpha is associated with ischemic tolerance in human stroke. Ann Neurol 54:811–819

    CAS  PubMed  Google Scholar 

  • Catrina AI, Lampa J, Ernestam S, af Klint E, Bratt J, Klareskog L, Ulfgren AK (2002) Anti-tumour necrosis factor (TNF)-alpha therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis. Rheumatology (Oxf) 41:484–489

    CAS  Google Scholar 

  • Catrina AI, Trollmo C, af Klint E, Engstrom M, Lampa J, Hermansson Y, Klareskog L, Ulfgren AK (2005) Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report. Arthritis Rheum 52:61–72

    CAS  PubMed  Google Scholar 

  • Cawthorn WP, Heyd F, Hegyi K, Sethi JK (2007) Tumour necrosis factor-alpha inhibits adipogenesis via a beta-catenin/TCF4(TCF7L2)-dependent pathway. Cell Death Differ 14:1361–1373

    CAS  PubMed  Google Scholar 

  • Charles P, Elliott MJ, Davis D, Potter A, Kalden JR, Antoni C, Breedveld FC, Smolen JS, Eberl G, deWoody K, Feldmann M, Maini RN (1999) Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol 163:1521–1528

    CAS  PubMed  Google Scholar 

  • Chee J, Angstetra E, Mariana L, Graham KL, Carrington EM, Bluethmann H, Santamaria P, Allison J, Kay TW, Krishnamurthy B, Thomas HE (2011) TNF receptor 1 deficiency increases regulatory T cell function in nonobese diabetic mice. J Immunol 187:1702–1712

    CAS  PubMed  Google Scholar 

  • Chen X, Baumel M, Mannel DN, Howard OM, Oppenheim JJ (2007) Interaction of TNF with TNF receptor type 2 promotes expansion and function of mouse CD4+CD25+ T regulatory cells. J Immunol 179:154–161

    CAS  PubMed  Google Scholar 

  • Chen X, Subleski JJ, Kopf H, Howard OM, Mannel DN, Oppenheim JJ (2008) Cutting edge: expression of TNFR2 defines a maximally suppressive subset of mouse CD4+CD25+FoxP3+ T regulatory cells: applicability to tumor-infiltrating T regulatory cells. J Immunol 180:6467–6471

    CAS  PubMed  Google Scholar 

  • Chen X, Subleski JJ, Hamano R, Howard OM, Wiltrout RH, Oppenheim JJ (2010) Co-expression of TNFR2 and CD25 identifies more of the functional CD4+FOXP3+ regulatory T cells in human peripheral blood. Eur J Immunol 40:1099–1106

    CAS  PubMed  Google Scholar 

  • Chertoff M, Di Paolo N, Schoeneberg A, Depino A, Ferrari C, Wurst W, Pfizenmaier K, Eisel U, Pitossi F (2011) Neuroprotective and neurodegenerative effects of the chronic expression of tumor necrosis factor alpha in the nigrostriatal dopaminergic circuit of adult mice. Exp Neurol 227:237–251

    CAS  PubMed  Google Scholar 

  • Christen U, Wolfe T, Mohrle U, Hughes AC, Rodrigo E, Green EA, Flavell RA, von Herrath MG (2001) A dual role for TNF-alpha in type 1 diabetes: islet-specific expression abrogates the ongoing autoimmune process when induced late but not early during pathogenesis. J Immunol 166:7023–7032

    CAS  PubMed  Google Scholar 

  • Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT, Anti TNFTACHFI (2003) Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 107:3133–3140

    CAS  PubMed  Google Scholar 

  • Cinti S, Mitchell G, Barbatelli G, Murano I, Ceresi E, Faloia E, Wang S, Fortier M, Greenberg AS, Obin MS (2005) Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J Lipid Res 46:2347–2355

    CAS  PubMed  Google Scholar 

  • Cope AP (2003) Exploring the reciprocal relationship between immunity and inflammation in chronic inflammatory arthritis. Rheumatology (Oxf) 42:716–731

    CAS  Google Scholar 

  • Cope AP, Aderka D, Doherty M, Engelmann H, Gibbons D, Jones AC, Brennan FM, Maini RN, Wallach D, Feldmann M (1992) Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases. Arthritis Rheum 35:1160–1169

    CAS  PubMed  Google Scholar 

  • Distler JH, Schett G, Gay S, Distler O (2008) The controversial role of tumor necrosis factor alpha in fibrotic diseases. Arthritis Rheum 58:2228–2235

    CAS  PubMed  Google Scholar 

  • Domercq M, Brambilla L, Pilati E, Marchaland J, Volterra A, Bezzi P (2006) P2Y1 receptor-evoked glutamate exocytosis from astrocytes: control by tumor necrosis factor-alpha and prostaglandins. J Biol Chem 281:30684–30696

    CAS  PubMed  Google Scholar 

  • Dziewulska D, Mossakowski MJ (2003) Cellular expression of tumor necrosis factor α and its receptors in human ischemic stroke. Clin Neuropathol 22:35–40

    CAS  PubMed  Google Scholar 

  • Ehrenstein MR, Evans JG, Singh A, Moore S, Warnes G, Isenberg DA, Mauri C (2004) Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J Exp Med 200:277–285

    CAS  PubMed  Google Scholar 

  • Eissner G, Kolch W, Scheurich P (2004) Ligands working as receptors: reverse signaling by members of the TNF superfamily enhance the plasticity of the immune system. Cytokine Growth Factor Rev 15:353–366

    CAS  PubMed  Google Scholar 

  • Elicabe RJ, Cargnelutti E, Serer MI, Stege PW, Valdez SR, Toscano MA, Rabinovich GA, Di Genaro MS (2010) Lack of TNFR p55 results in heightened expression of IFN-gamma and IL-17 during the development of reactive arthritis. J Immunol 185:4485–4495

    CAS  PubMed  Google Scholar 

  • Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Bijl H, Woody JN (1994) Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet 344:1125–1127

    CAS  PubMed  Google Scholar 

  • Feldmann M (2009) Translating molecular insights in autoimmunity into effective therapy. Annu Rev Immunol 27:1–27

    CAS  PubMed  Google Scholar 

  • Feldmann M, Maini RN (2001) Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 19:163–196

    CAS  PubMed  Google Scholar 

  • Feldmann M, Maini RN (2003) Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat Med 9:1245–1250

    CAS  PubMed  Google Scholar 

  • Feldmann M, Maini RN (2010) Anti-TNF therapy, from rationale to standard of care: what lessons has it taught us? J Immunol 185:791–794

    CAS  PubMed  Google Scholar 

  • Feldmann M, Brennan FM, Maini RN (1996) Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 14:397–440

    CAS  PubMed  Google Scholar 

  • Fiore M, Angelucci F, Alleva E, Branchi I, Probert L, Aloe L (2000) Learning performances, brain NGF distribution and NPY levels in transgenic mice expressing TNF-alpha. Behav Brain Res 112:165–175

    CAS  PubMed  Google Scholar 

  • Fong Y, Tracey KJ, Moldawer LL, Hesse DG, Manogue KB, Kenney JS, Lee AT, Kuo GC, Allison AC, Lowry SF, Cerami A (1989) Antibodies to cachectin/tumor necrosis factor reduce interleukin 1 beta and interleukin 6 appearance during lethal bacteremia. J Exp Med 170:1627–1633

    CAS  PubMed  Google Scholar 

  • Fromont A, De Seze J, Fleury MC, Maillefert JF, Moreau T (2009) Inflammatory demyelinating events following treatment with anti-tumor necrosis factor. Cytokine 45:55–57

    CAS  PubMed  Google Scholar 

  • Fujita M, Shannon JM, Morikawa O, Gauldie J, Hara N, Mason RJ (2003) Overexpression of tumor necrosis factor-alpha diminishes pulmonary fibrosis induced by bleomycin or transforming growth factor-beta. Am J Respir Cell Mol Biol 29:669–676

    CAS  PubMed  Google Scholar 

  • Gearing AJ, Beckett P, Christodoulou M, Churchill M, Clements J, Davidson AH, Drummond AH, Galloway WA, Gilbert R, Gordon JL et al (1994) Processing of tumour necrosis factor-alpha precursor by metalloproteinases. Nature (Lond) 370:555–557

    CAS  Google Scholar 

  • Glass GE, Chan JK, Freidin A, Feldmann M, Horwood NJ, Nanchahal J (2011) TNF-alpha promotes fracture repair by augmenting the recruitment and differentiation of muscle-derived stromal cells. Proc Natl Acad Sci USA 108:1585–1590

    CAS  PubMed  Google Scholar 

  • Goekoop-Ruiteman YP, de Vries-Bouwstra JK, Allaart CF et al (2005) Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 11:3381–3390

    Google Scholar 

  • Gonzalez-Gay MA, Gonzalez-Juanatey C, Martin J (2005) Rheumatoid arthritis: a disease associated with accelerated atherogenesis. Semin Arthritis Rheum 35:8–17

    PubMed  Google Scholar 

  • Gorell JM, Peterson EL, Rybicki BA, Johnson CC (2004) Multiple risk factors for Parkinson’s disease. J Neurol Sci 217:169–174

    PubMed  Google Scholar 

  • Goshen I, Kreisel T, Ounallah-Saad H, Renbaum P, Zalzstein Y, Ben-Hur T, Levy-Lahad E, Yirmiya R (2007) A dual role for interleukin-1 in hippocampal-dependent memory processes. Psychoneuroendocrinology 32:1106–1115

    CAS  PubMed  Google Scholar 

  • Grell M, Douni E, Wajant H, Lohden M, Clauss M, Maxeiner B, Georgopolous S, Lesslauer W, Kollias G, Pfizenmaier K, Scheurich P (1995) The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 83(5):793–802

    CAS  PubMed  Google Scholar 

  • Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC, Spertus JA, Costa F, American Heart Association, National Heart, Lung, and Blood Institute (2005) Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation 112:2735–2752

    PubMed  Google Scholar 

  • Gullestad L, Ueland T, Vinge LE, Finsen A, Yndestad A, Aukrust P (2012) Inflammatory cytokines in heart failure: mediators and markers. Cardiology 122:23–35

    CAS  PubMed  Google Scholar 

  • Guo G, Morrissey J, McCracken R, Tolley T, Klahr S (1999) Role of TNFR1 and TNFR2 receptors in tubulointerstitial fibrosis of obstructive nephropathy. Am J Physiol 277:F766–F772

    CAS  PubMed  Google Scholar 

  • Gustafson B, Smith U (2006) Cytokines promote Wnt signaling and inflammation and impair the normal differentiation and lipid accumulation in 3T3-L1 preadipocytes. J Biol Chem 281:9507–9516

    CAS  PubMed  Google Scholar 

  • Hamano R, Huang J, Yoshimura T, Oppenheim JJ, Chen X (2011) TNF optimally activatives regulatory T cells by inducing TNF receptor superfamily members TNFR2, 4-1BB and OX40. Eur J Immunol 41:2010–2020

    CAS  PubMed  Google Scholar 

  • Heldmann U, Thored P, Claasen JH, Arvidsson A, Kokaia Z, Lindvall O (2005) TNF-alpha antibody infusion impairs survival of stroke-generated neuroblasts in adult rat brain. Exp Neurol 196:204–208

    CAS  PubMed  Google Scholar 

  • Holtmann MH, Schuchmann M, Zeller G, Galle PR, Neurath MF (2002) The emerging distinct role of TNF-receptor 2 (p80) signaling in chronic inflammatory disorders. Arch Immunol Ther Exp (Warsz) 50:279–288

    CAS  Google Scholar 

  • Housley WJ, Adams CO, Nichols FC, Puddington L, Lingenheld EG, Zhu L, Rajan TV, Clark RB (2011) Natural but not inducible regulatory T cells require TNF-alpha signaling for in vivo function. J Immunol 186:6779–6787

    CAS  PubMed  Google Scholar 

  • Jacob CO, McDevitt HO (1988) Tumour necrosis factor-alpha in murine autoimmune “lupus” nephritis. Nature (Lond) 331:356–358

    CAS  Google Scholar 

  • Jacobsson LT, Turesson C, Nilsson JA, Petersson IF, Lindqvist E, Saxne T, Geborek P (2007) Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis. Ann Rheum Dis 66:670–675

    PubMed  Google Scholar 

  • Kassiotis G, Kollias G (2001) Uncoupling the proinflammatory from the immunosuppressive properties of tumor necrosis factor (TNF) at the p55 TNF receptor level: implications for pathogenesis and therapy of autoimmune demyelination. J Exp Med 193:427–434

    CAS  PubMed  Google Scholar 

  • Keffer J, Probert L, Cazlaris H, Georgopoulos S, Kaslaris E, Kioussis D, Kollias G (1991) Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 10:4025–4031

    CAS  PubMed  Google Scholar 

  • Kelchtermans H, De Klerck B, Mitera T, Van Balen M, Bullens D, Billiau A, Leclercq G, Matthys P (2005) Defective CD4+CD25+ regulatory T cell functioning in collagen-induced arthritis: an important factor in pathogenesis, counter-regulated by endogenous IFN-gamma. Arthritis Res Ther 7:R402–R415

    CAS  PubMed  Google Scholar 

  • Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G (2001) Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 280:E745–E751

    CAS  PubMed  Google Scholar 

  • Khan SB, Cook HT, Bhangal G, Smith J, Tam FW, Pusey CD (2005) Antibody blockade of TNF-alpha reduces inflammation and scarring in experimental crescentic glomerulonephritis. Kidney Int 67:1812–1820

    CAS  PubMed  Google Scholar 

  • Kim EY, Chi HH, Rajaiah R, Moudgil KD (2008) Exogenous tumor necrosis factor-alpha induces suppression of autoimmune arthritis. Arthritis Res Ther 10:R38

    CAS  PubMed  Google Scholar 

  • Kim YS, Park HJ, Hong MH, Kang PM, Morgan JP, Jeong MH, Cho JG, Park JC, Ahn Y (2009) TNF-alpha enhances engraftment of mesenchymal stem cells into infarcted myocardium. Front Biosci 14:2845–2856

    CAS  Google Scholar 

  • Kiortsis DN, Mavridis AK, Vasakos S, Nikas SN, Drosos AA (2005) Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis. Ann Rheum Dis 64:765–766

    CAS  PubMed  Google Scholar 

  • Kitamura K, Nakamoto Y, Akiyama M, Fujii C, Kondo T, Kobayashi K, Kaneko S, Mukaida N (2002) Pathogenic roles of tumor necrosis factor receptor p55-mediated signals in dimethylnitrosamine-induced murine liver fibrosis. Lab Invest 82:571–583

    CAS  PubMed  Google Scholar 

  • Kleijwegt FS, Laban S, Duinkerken G, Joosten AM, Zaldumbide A, Nikolic T, Roep BO (2010) Critical role for TNF in the induction of human antigen-specific regulatory T cells by tolerogenic dendritic cells. J Immunol 185:1412–1418

    CAS  PubMed  Google Scholar 

  • Kollias G (2005) TNF pathophysiology in murine models of chronic inflammation and autoimmunity. Semin Arthritis Rheum 34:3–6

    CAS  PubMed  Google Scholar 

  • Kollias G, Kontoyiannis D (2002) Role of TNF/TNFR in autoimmunity: specific TNF receptor blockade may be advantageous to anti-TNF treatments. Cytokine Growth Factor Rev 13:315–321

    CAS  PubMed  Google Scholar 

  • Kontoyiannis D, Kollias G (2000) Accelerated autoimmunity and lupus nephritis in NZB mice with an engineered heterozygous deficiency in tumor necrosis factor. Eur J Immunol 30:2038–2047

    CAS  PubMed  Google Scholar 

  • Kontoyiannis D, Pasparakis M, Pizarro TT, Cominelli F, Kollias G (1999) Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. Immunity 10:387–398

    CAS  PubMed  Google Scholar 

  • Korn T, Reddy J, Gao W, Bettelli E, Awasthi A, Petersen TR, Backstrom BT, Sobel RA, Wucherpfennig KW, Strom TB, Oukka M, Kuchroo VK (2007) Myelin-specific regulatory T cells accumulate in the CNS but fail to control autoimmune inflammation. Nat Med 13:423–431

    CAS  PubMed  Google Scholar 

  • Kubota T, McTiernan CF, Frye CS, Slawson SE, Lemster BH, Koretsky AP, Demetris AJ, Feldman AM (1997) Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. Circ Res 81:627–635

    CAS  PubMed  Google Scholar 

  • Lam GK, Hummers LK, Woods A, Wigley FM (2007) Efficacy and safety of etanercept in the treatment of scleroderma-associated joint disease. J Rheumatol 34:1636–1637

    PubMed  Google Scholar 

  • Lavine SD, Hofman FM, Zlokovic BV (1998) Circulating antibody against tumor necrosis factor-alpha protects rat brain from reperfusion injury. J Cereb Blood Flow Metab 18:52–58

    CAS  PubMed  Google Scholar 

  • Lawson LJ, Perry VH, Dri P, Gordon S (1990) Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. Neuroscience 39:151–170

    CAS  PubMed  Google Scholar 

  • Lindley S, Dayan CM, Bishop A, Roep BO, Peakman M, Tree TI (2005) Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes. Diabetes 54:92–99

    CAS  PubMed  Google Scholar 

  • Listing J, Strangfeld A, Kekow J, Schneider M, Kapelle A, Wassenberg S, Zink A (2008) Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis? Arthritis Rheum 58:667–677

    CAS  PubMed  Google Scholar 

  • Liu J, Marino MW, Wong G, Grail D, Dunn A, Bettadapura J, Slavin AJ, Old L, Bernard CC (1998a) TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination. Nat Med 4:78–83

    CAS  PubMed  Google Scholar 

  • Liu JY, Brass DM, Hoyle GW, Brody AR (1998b) TNF-alpha receptor knockout mice are protected from the fibroproliferative effects of inhaled asbestos fibers. Am J Pathol 153:1839–1847

    CAS  PubMed  Google Scholar 

  • Lorenz HM, Antoni C, Valerius T, Repp R, Grunke M, Schwerdtner N, Nusslein H, Woody J, Kalden JR, Manger B (1996) In vivo blockade of TNF-alpha by intravenous infusion of a chimeric monoclonal TNF-alpha antibody in patients with rheumatoid arthritis—short term cellular and molecular effects. J Immunol 156:1646–1653

    CAS  PubMed  Google Scholar 

  • Lu Z, Wang G, Dunstan CR, Zreiqat H (2012) Short-term exposure to tumor necrosis factor-alpha enables human osteoblasts to direct adipose tissue-derived mesenchymal stem cells into osteogenic differentiation. Stem Cells Dev 21:2420–2429

    CAS  PubMed  Google Scholar 

  • Ma X, Sun J, Papasavvas E, Riemann H, Robertson S, Marshall J, Bailer RT, Moore A, Donnelly RP, Trinchieri G, Montaner LJ (2000) Inhibition of IL-12 production in human monocyte-derived macrophages by TNF. J Immunol 164:1722–1729

    CAS  PubMed  Google Scholar 

  • Ma HL, Napierata L, Stedman N, Benoit S, Collins M, Nickerson-Nutter C, Young DA (2010) Tumor necrosis factor alpha blockade exacerbates murine psoriasis-like disease by enhancing Th17 function and decreasing expansion of Treg cells. Arthritis Rheum 62:430–440

    CAS  PubMed  Google Scholar 

  • McAfoose J, Baune BT (2009) Evidence for a cytokine model of cognitive function. Neurosci Biobehav Rev 33:355–366

    CAS  PubMed  Google Scholar 

  • McCoy MK, Tansey MG (2008) TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease. J Neuroinflammation 5:45

    PubMed  Google Scholar 

  • McKellar GE, McCarey DW, Sattar N, McInnes IB (2009) Role for TNF in atherosclerosis? Lessons from autoimmune disease. Nat Rev Cardiol 6:410–417

    CAS  PubMed  Google Scholar 

  • Meikle MC, Atkinson SJ, Ward RV, Murphy G, Reynolds JJ (1989) Gingival fibroblasts degrade type I collagen films when stimulated with tumor necrosis factor and interleukin 1: evidence that breakdown is mediated by metalloproteinases. J Periodont Res 24:207–213

    CAS  PubMed  Google Scholar 

  • Miyazaki Y, Araki K, Vesin C, Garcia I, Kapanci Y, Whitsett JA, Piguet PF, Vassalli P (1995) Expression of a tumor necrosis factor-alpha transgene in murine lung causes lymphocytic and fibrosing alveolitis. A mouse model of progressive pulmonary fibrosis. J Clin Invest 96:250–259

    CAS  PubMed  Google Scholar 

  • Montgomery SL, Bowers WJ (2012) Tumor necrosis factor-alpha and the roles it plays in homeostatic and degenerative processes within the central nervous system. J Neuroimmune Pharmacol 7:42–59

    PubMed  Google Scholar 

  • Moreland LW, O’Dell JR, Paulus HE, Curtis JR, Bathon JM, St. Clair EW, Bridges SL Jr, Zhang J, McVie T, Howard G, van der Heijde D, Cofield SS (2012) A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of early aggressive rheumatoid arthritis trial. Arthritis Rheum 64:2824–2835

    CAS  PubMed  Google Scholar 

  • Nadkarni S, Mauri C, Ehrenstein MR (2007) Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta. J Exp Med 204:33–39

    CAS  PubMed  Google Scholar 

  • Nawashiro H, Martin D, Hallenbeck JM (1997) Neuroprotective effects of TNF binding protein in focal cerebral ischemia. Brain Res 778:265–271

    CAS  PubMed  Google Scholar 

  • Nieto-Vazquez I, Fernandez-Veledo S, Kramer DK, Vila-Bedmar R, Garcia-Guerra L, Lorenzo M (2008) Insulin resistance associated to obesity: the link TNF-alpha. Arch Physiol Biochem 114:183–194

    CAS  PubMed  Google Scholar 

  • Notley CA, Inglis JJ, Alzabin S, McCann FE, McNamee KE, Williams RO (2008) Blockade of tumor necrosis factor in collagen-induced arthritis reveals a novel immunoregulatory pathway for Th1 and Th17 cells. J Exp Med 205:2491–2497

    CAS  PubMed  Google Scholar 

  • Ofei F, Hurel S, Newkirk J, Sopwith M, Taylor R (1996) Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes 45:881–885

    PubMed  Google Scholar 

  • Ortiz LA, Lasky J, Hamilton RF Jr, Holian A, Hoyle GW, Banks W, Peschon JJ, Brody AR, Lungarella G, Friedman M (1998) Expression of TNF and the necessity of TNF receptors in bleomycin-induced lung injury in mice. Exp Lung Res 24:721–743

    CAS  PubMed  Google Scholar 

  • Ortiz LA, Lasky J, Lungarella G, Cavarra E, Martorana P, Banks WA, Peschon JJ, Schmidts HL, Brody AR, Friedman M (1999) Upregulation of the p75 but not the p55 TNF-alpha receptor mRNA after silica and bleomycin exposure and protection from lung injury in double receptor knockout mice. Am J Respir Cell Mol Biol 20:825–833

    CAS  PubMed  Google Scholar 

  • Paleolog EM, Hunt M, Elliott MJ, Feldmann M, Maini RN, Woody JN (1996) Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor α antibody in rheumatoid arthritis. Arthritis Rheum 39:1082–1091

    CAS  PubMed  Google Scholar 

  • Paleolog EM, Young S, Stark AC, McCloskey RV, Feldmann M, Maini RN (1998) Modulation of angiogenic vascular endothelial growth factor (VEGF) by TNFα and IL-1 in rheumatoid arthritis. Arthritis Rheum 41:1258–1265

    CAS  PubMed  Google Scholar 

  • Pennica D, Hayflick JS, Bringman TS, Palladino MA, Goeddel DV (1985) Cloning and expression in Escherichia coli of the cDNA for murine tumour necrosis factor. Proc Natl Acad Sci USA 82(18):6060–6064

    CAS  PubMed  Google Scholar 

  • Peschon JJ, Slack JL, Reddy P, Stocking KL, Sunnarborg SW, Lee DC, Russell WE, Castner BJ, Johnson RS, Fitzner JN, Boyce RW, Nelson N, Kozlosky CJ, Wolfson MF, Rauch CT, Cerretti DP, Paxton RJ, March CJ, Black RA (1998) An essential role for ectodomain shedding in mammalian development. Science 282:1281–1284

    CAS  PubMed  Google Scholar 

  • Pfeiffer A, Janott J, Mohlig M, Ristow M, Rochlitz H, Busch K, Schatz H, Schifferdecker E (1997) Circulating tumor necrosis factor alpha is elevated in male but not in female patients with type II diabetes mellitus. Horm Metab Res 29:111–114

    CAS  PubMed  Google Scholar 

  • Piguet PF, Vesin C (1994) Treatment by human recombinant soluble TNF receptor of pulmonary fibrosis induced by bleomycin or silica in mice. Eur Respir J 7:515–518

    CAS  PubMed  Google Scholar 

  • Piguet PF, Collart MA, Grau GE, Sappino AP, Vassalli P (1990) Requirement of tumour necrosis factor for development of silica-induced pulmonary fibrosis. Nature 344:245–247

    CAS  PubMed  Google Scholar 

  • Piguet PF, Grau GE, Vesin C, Loetscher H, Gentz R, Lesslauer W (1992) Evolution of collagen arthritis in mice is arrested by treatment with anti-tumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor. Immunology 77:510–514

    CAS  PubMed  Google Scholar 

  • Probert L, Plows D, Kontogeorgos G, Kollias G (1995) The type I interleukin-1 receptor acts in series with tumor necrosis factor (TNF) to induce arthritis in TNF-transgenic mice. Eur J Immunol 25:1794–1797

    CAS  PubMed  Google Scholar 

  • Ramos-Casals M, Perez-Alvarez R, Perez-de-Lis M, Xaubet A, Bosch X, Group BS (2011) Pulmonary disorders induced by monoclonal antibodies in patients with rheumatologic autoimmune diseases. Am J Med 124:386–394

    CAS  PubMed  Google Scholar 

  • Ren L, Lubrich B, Biber K, Gebicke-Haerter PJ (1999) Differential expression of inflammatory mediators in rat microglia cultured from different brain regions. Brain Res Mol Brain Res 65:198–205

    CAS  PubMed  Google Scholar 

  • Ryba M, Marek N, Hak L, Rybarczyk-Kapturska K, Mysliwiec M, Trzonkowski P, Mysliwska J (2011) Anti-TNF rescue CD4+Foxp3+ regulatory T cells in patients with type 1 diabetes from effects mediated by TNF. Cytokine 55:353–361

    CAS  PubMed  Google Scholar 

  • Ryden M, Arner P (2007) Tumour necrosis factor-alpha in human adipose tissue—from signalling mechanisms to clinical implications. J Intern Med 262:431–438

    CAS  PubMed  Google Scholar 

  • Satoh J, Seino H, Abo T, Tanaka S, Shintani S, Ohta S, Tamura K, Sawai T, Nobunaga T, Oteki T et al (1989) Recombinant human tumor necrosis factor alpha suppresses autoimmune diabetes in nonobese diabetic mice. J Clin Invest 84:1345–1348

    CAS  PubMed  Google Scholar 

  • Sethi JK, Hotamisligil GS (1999) The role of TNF alpha in adipocyte metabolism. Semin Cell Dev Biol 10:19–29

    CAS  PubMed  Google Scholar 

  • Sime PJ, Marr RA, Gauldie D, Xing Z, Hewlett BR, Graham FL, Gauldie J (1998) Transfer of tumor necrosis factor-alpha to rat lung induces severe pulmonary inflammation and patchy interstitial fibrogenesis with induction of transforming growth factor-beta1 and myofibroblasts. Am J Pathol 153:825–832

    CAS  PubMed  Google Scholar 

  • Smeets TJ, Kraan MC, van Loon ME, Tak PP (2003) Tumor necrosis factor alpha blockade reduces the synovial cell infiltrate early after initiation of treatment, but apparently not by induction of apoptosis in synovial tissue. Arthritis Rheum 48:2155–2162

    CAS  PubMed  Google Scholar 

  • Smolen JS, Landewe R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, Gorter S, Knevel R, Nam J, Schoels M, Aletaha D, Buch M, Gossec L, Huizinga T, Bijlsma JW, Burmester G, Combe B, Cutolo M, Gabay C, Gomez-Reino J, Kouloumas M, Kvien TK, Martin-Mola E, McInnes I, Pavelka K, van Riel P, Scholte M, Scott DL, Sokka T, Valesini G, van Vollenhoven R, Winthrop KL, Wong J, Zink A, van der Heijde D (2010) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 69:964–975

    CAS  PubMed  Google Scholar 

  • Smookler DS, Mohammed FF, Kassiri Z, Duncan GS, Mak TW, Khokha R (2006) Tissue inhibitor of metalloproteinase 3 regulates TNF-dependent systemic inflammation. J Immunol 176:721–725

    CAS  PubMed  Google Scholar 

  • Sriram K, O’Callaghan JP (2007) Divergent roles for tumor necrosis factor-alpha in the brain. J Neuroimmune Pharmacol 2:140–153

    PubMed  Google Scholar 

  • Sriram K, Matheson JM, Benkovic SA, Miller DB, Luster MI, O’Callaghan JP (2006) Deficiency of TNF receptors suppresses microglial activation and alters the susceptibility of brain regions to MPTP-induced neurotoxicity: role of TNF-alpha. FASEB J 20:670–682

    CAS  PubMed  Google Scholar 

  • Stavropoulos-Kalinoglou A, Metsios GS, Panoulas VF, Nightingale P, Koutedakis Y, Kitas GD (2012) Anti-tumour necrosis factor alpha therapy improves insulin sensitivity in normal-weight but not in obese patients with rheumatoid arthritis. Arthritis Res Ther 14:R160

    CAS  PubMed  Google Scholar 

  • Stellwagen D, Malenka RC (2006) Synaptic scaling mediated by glial TNF-alpha. Nature (Lond) 440:1054–1059

    CAS  Google Scholar 

  • Sudo K, Yamada Y, Moriwaki H, Saito K, Seishima M (2005) Lack of tumor necrosis factor receptor type 1 inhibits liver fibrosis induced by carbon tetrachloride in mice. Cytokine 29:236–244

    CAS  PubMed  Google Scholar 

  • Suganami T, Ogawa Y (2010) Adipose tissue macrophages: their role in adipose tissue remodeling. J Leukoc Biol 88:33–39

    CAS  PubMed  Google Scholar 

  • Sullivan DE, Ferris M, Pociask D, Brody AR (2005) Tumor necrosis factor-alpha induces transforming growth factor-beta1 expression in lung fibroblasts through the extracellular signal-regulated kinase pathway. Am J Respir Cell Mol Biol 32:342–349

    CAS  PubMed  Google Scholar 

  • Tak PP, Taylor PC, Breedveld FC, Smeets TJM, Daha MR, Kluin PM, Meinders AE, Maini RN (1996) Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor α monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum 39:1077–1081

    CAS  PubMed  Google Scholar 

  • Tam CS, Clement K, Baur LA, Tordjman J (2010) Obesity and low-grade inflammation: a paediatric perspective. Obes Rev 11:118–126

    CAS  PubMed  Google Scholar 

  • Tartaglia LA, Pennica D, Goeddel DV (1993) Ligand passing: the 75-kDa tumor necrosis factor (TNF) receptor recruits TNF for signaling by the 55-kDa TNF receptor. J Biol Chem 268:18542–18548

    CAS  PubMed  Google Scholar 

  • Taylor PC (2005) Serum vascular markers and vascular imaging in assessment of rheumatoid arthritis disease activity and response to therapy. Rheumatology (Oxf) 44:721–728

    CAS  Google Scholar 

  • Taylor PC (2010) Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases. Curr Opin Pharmacol 10:308–315

    CAS  PubMed  Google Scholar 

  • Taylor PC, Peters AM, Glass DM, Maini RN (1999) Effects of treatment of rheumatoid arthritis patients with an antibody against tumour necrosis factor alpha on reticuloendothelial and intrapulmonary granulocyte traffic. Clin Sci (Lond) 97:85–89

    CAS  Google Scholar 

  • Taylor PC, Peters AM, Paleolog E, Chapman PT, Elliott MJ, McCloskey R, Feldmann M, Maini RN (2000) Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor α blockade in patients with rheumatoid arthritis. Arthritis Rheum 43:38–47

    CAS  PubMed  Google Scholar 

  • Taylor PC, Steuer A, Gruber J, Cosgrove DO, Blomley MJ, Marsters PA, Wagner CL, McClinton C, Maini RN (2004) Comparison of ultrasonographic assessment of synovitis and joint vascularity with radiographic evaluation in a randomized, placebo-controlled study of infliximab therapy in early rheumatoid arthritis. Arthritis Rheum 50:1107–1116

    CAS  PubMed  Google Scholar 

  • Taylor PC, Steuer A, Gruber J, McClinton C, Cosgrove DO, Blomley MJ, Marsters PA, Wagner CL, Maini RN (2006) Ultrasonographic and radiographic results from a two-year controlled trial of immediate or one-year-delayed addition of infliximab to ongoing methotrexate therapy in patients with erosive early rheumatoid arthritis. Arthritis Rheum 54:47–53

    CAS  PubMed  Google Scholar 

  • Terrando N, Monaco C, Ma D, Foxwell BM, Feldmann M, Maze M (2010) Tumor necrosis factor-alpha triggers a cytokine cascade yielding postoperative cognitive decline. Proc Natl Acad Sci USA 107:20518–20522

    CAS  PubMed  Google Scholar 

  • Terrando N, Eriksson LI, Ryu JK, Yang T, Monaco C, Feldmann M, Jonsson Fagerlund M, Charo IF, Akassoglou K, Maze M (2011) Resolving postoperative neuroinflammation and cognitive decline. Ann Neurol 70:986–995

    CAS  PubMed  Google Scholar 

  • Theiss AL, Simmons JG, Jobin C, Lund PK (2005) Tumor necrosis factor (TNF) alpha increases collagen accumulation and proliferation in intestinal myofibroblasts via TNF receptor 2. J Biol Chem 280:36099–36109

    CAS  PubMed  Google Scholar 

  • Thorbecke GJ, Shah R, Leu CH, Kuruvilla AP, Hardison AM, Palladino MA (1992) Involvement of endogenous tumor necrosis factor α and transforming growth factor β during induction of collagen type II arthritis in mice. Proc Natl Acad Sci USA 89:7375–7379

    CAS  PubMed  Google Scholar 

  • Toubi E, Kessel A, Mahmudov Z, Hallas K, Rozenbaum M, Rosner I (2005) Increased spontaneous apoptosis of CD4+CD25+ T cells in patients with active rheumatoid arthritis is reduced by infliximab. Ann N Y Acad Sci 1051:506–514

    CAS  PubMed  Google Scholar 

  • Triantaphyllopoulos K, Croxford J, Baker D, Chernajovsky Y (1998) Cloning and expression of murine IFN beta and a TNF antagonist for gene therapy of experimental allergic encephalomyelitis. Gene Ther 5:253–263

    CAS  PubMed  Google Scholar 

  • Ulfgren AK, Andersson U, Engstrom M, Klareskog L, Maini RN, Taylor PC (2000) Systemic anti-tumor necrosis factor alpha therapy in rheumatoid arthritis down-regulates synovial tumor necrosis factor alpha synthesis. Arthritis Rheum 43:2391–2396

    CAS  PubMed  Google Scholar 

  • Valencia X, Stephens G, Goldbach-Mansky R, Wilson M, Shevach EM, Lipsky PE (2006) TNF downmodulates the function of human CD4+CD25hi T-regulatory cells. Blood 108:253–261

    CAS  PubMed  Google Scholar 

  • van Amelsfort JM, van Roon JA, Noordegraaf M, Jacobs KM, Bijlsma JW, Lafeber FP, Taams LS (2007) Proinflammatory mediator-induced reversal of CD4+, CD25+ regulatory T cell-mediated suppression in rheumatoid arthritis. Arthritis Rheum 56:732–742

    PubMed  Google Scholar 

  • van Vollenhoven RF, Ernestam S, Geborek P, Petersson IF, Coster L, Waltbrand E, Zickert A, Theander J, Thorner A, Hellstrom H, Teleman A, Dackhammar C, Akre F, Forslind K, Ljung L, Oding R, Chatzidionysiou A, Wornert M, Bratt J (2009) Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. Lancet 374:459–466

    PubMed  Google Scholar 

  • Verjee LS, Verhoekx JSN, Chan JK, Krausgruber T, Nicolaidou V, Izadi D, Davidson D, Feldmann M, Midwood KS, Nanchahal J (2013) Unravelling the signaling pathways promoting fibrosis in Dupuytren's disease reveals TNF as a therapeutic target. Proc Natl Acad Sci USA 110:E928–E937

    CAS  PubMed  Google Scholar 

  • Verrecchia F, Pessah M, Atfi A, Mauviel A (2000) Tumor necrosis factor-alpha inhibits transforming growth factor-beta/smad signaling in human dermal fibroblasts via AP-1 activation. J Biol Chem 275:30226–30231

    CAS  PubMed  Google Scholar 

  • Viglietta V, Baecher-Allan C, Weiner HL, Hafler DA (2004) Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med 199:971–979

    CAS  PubMed  Google Scholar 

  • Williams RO, Feldmann M, Maini RN (1992) Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci USA 89:9784–9788

    CAS  PubMed  Google Scholar 

  • Williams RO, Ghrayeb J, Feldmann M, Maini RN (1995) Successful therapy of collagen-induced arthritis with TNF receptor-IgG fusion protein and combination with anti-CD4. Immunology 84:433–439

    CAS  PubMed  Google Scholar 

  • Wynn TA (2008) Cellular and molecular mechanisms of fibrosis. J Pathol 214:199–210

    CAS  PubMed  Google Scholar 

  • Yazdani-Biuki B, Stelzl H, Brezinschek HP, Hermann J, Mueller T, Krippl P, Graninger W, Wascher TC (2004) Improvement of insulin sensitivity in insulin resistant subjects during prolonged treatment with the anti-TNF-alpha antibody infliximab. Eur J Clin Invest 34:641–642

    CAS  PubMed  Google Scholar 

  • Zakharova M, Ziegler HK (2005) Paradoxical anti-inflammatory actions of TNF-alpha: inhibition of IL-12 and IL-23 via TNF receptor 1 in macrophages and dendritic cells. J Immunol 175:5024–5033

    CAS  PubMed  Google Scholar 

  • Zhang H, Yan D, Shi X, Liang H, Pang Y, Qin N, Chen H, Wang J, Yin B, Jiang X, Feng W, Zhang W, Zhou M, Li Z (2008) Transmembrane TNF-alpha mediates “forward” and “reverse” signaling, inducing cell death or survival via the NF-kappaB pathway in Raji Burkitt lymphoma cells. J Leukoc Biol 84:789–797

    CAS  PubMed  Google Scholar 

  • Ziolkowska M, Kurowska M, Radzikowska A, Luszczykiewicz G, Wiland P, Dziewczopolski W, Filipowicz-Sosnowska A, Pazdur J, Szechinski J, Kowalczewski J, Rell-Bakalarska M, Maslinski W (2002) High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment. Arthritis Rheum 46:1744–1753

    CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The work described here involved very many colleagues. Chief among them are Professor Sir Ravinder Maini, who started working with Marc Feldmann in 1984. A colleague since 1987 who contributed hugely was Professor Fionula Brennan. Sadly, she died in June 2012. This was the topic to which she devoted most of her career, making invaluable contributions, and therefore this article is dedicated to her memory.

Author information

Authors and Affiliations

  1. Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Kennedy Institute of Rheumatology, University of Oxford, Roosevelt Drive, Headington, Oxford, OX3 7FY, UK

    Jagdeep Nanchahal, Richard Williams & Marc Feldmann

  2. Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Old Road, Headington, Oxford, OX3 7LD, UK

    Peter Taylor

Authors
  1. Jagdeep Nanchahal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter Taylor
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Richard Williams
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Marc Feldmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marc Feldmann .

Editor information

Editors and Affiliations

  1. Department of Immunoregulation Institute of Medical Science, Tokyo Medical University, Tokyo, Tokyo, Japan

    Takayuki Yoshimoto

  2. Institute for Advanced Medical Sciences, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan

    Tomohiro Yoshimoto

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Japan

About this chapter

Cite this chapter

Nanchahal, J., Taylor, P., Williams, R., Feldmann, M. (2014). Anti-TNF Therapy: 20 Years from Our First Therapeutic Adventure. In: Yoshimoto, T., Yoshimoto, T. (eds) Cytokine Frontiers. Springer, Tokyo. https://doi.org/10.1007/978-4-431-54442-5_9

Download citation

Publish with us

Policies and ethics

Search

Navigation